Concepedia

Publication | Open Access

Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha‐fetoprotein after sorafenib in REACH and REACH‐2

DOIFull Paper Access

31

Citations

14

References

2020

Year

Masatoshi Kudo, Peter R. Galle, Josep M. Llovet, Richard S. Finn, Arndt Vogel, Kenta Motomura, Eric Assénat, Philippe Merle, Giovanni Brandi, Bruno Daniele,
Liver International

Abstract

In this post-hoc analysis, ramucirumab showed a survival benefit across age subgroups with a tolerable safety profile, supporting its use in advanced HCC with elevated AFP, irrespective of age, including ≥75 years.

References

YearCitations

Page 1